The Centers for Disease Control and Prevention (CDC) The agency notes that obesity increases a persons risk of type 2 diabetes, high blood pressure, heart disease, stroke, and certain cancers
japonica , have garnered attention for their therapeutic potential
[2] [3] For many patients with established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors are preferred before GLP-1 receptor agonists where appropriate
Based on clinical trial data, tirzepatide produces superior weight loss results, but the better medication depends on individual factors beyond just numbers
A soluble form of LC3, LC3-I, is produced as a result of this reaction [29]